- Therapeutic drug and diagnostic company Fusion Antibodies reported narrower losses in the first half of the year compared with a year earlier as higher revenue offset increased costs.

For the six months ended 30 September 2020, pre-tax losses narrowed to £572,000 from £616,000 year-on-year as revenue increased to £1.90 million from £1.75 million, in line with management's expectations.

R&D expenditure rose 50% to £271,000.

Looking ahead, the company outlined two major uncertainties including Brexit and the impact of Covid-19 restrictions on its supply chain.

At 8:38am: [LON:FAB] Fusion Antibodies Plc Ord 4p share price was 0p at 132.5p

Story provided by